Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers-Reference-Cited by-同舟云学术

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers

Published:2003-10-22 Issue:S9 Volume:98 Page:2044-2051
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Follen Michele,Meyskens Frank L.,Alvarez Ronald D.,Walker Joan L.,Bell Maria C.,Adler Storthz Karen,Sastry Jagannadha,Roy Krishnendu,Richards-Kortum Rebecca,Cornelison Terri L.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference38 articles.

1. The 2001 Bethesda SystemTerminology for Reporting Results of Cervical Cytology

2. Chemoprevention trials and surrogate end point biomarkers in the cervix

3. Why Most Randomized Phase II Cervical Cancer Chemoprevention Trials are Uninformative: Lessons for the Future

4. Chemoprevention of cervix cancer: Phase I–II: A feasibility study involving the topical vaginal administration of retinyl acetate gel

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cervical Cancer Prevention;Fundamentals of Cancer Prevention;2019

2. In Vitro Evaluation of Cytotoxic and Antiproliferative Effects of Portulaca oleracea Ethanolic Extracton on HeLa Cell Line;Gene, Cell and Tissue;2016-11-16

3. Herbal product silibinin-induced programmed cell death is enhanced by metformin in cervical cancer cells at the dose without influence on nonmalignant cells;Journal of Applied Biomedicine;2015-05-01

4. The TLR3, PI3K, survin, FasL, and Fas genes as major risk factors of occurrence and development of cervical cancer disease;Gene;2014-10

5. Cervical Cancer Prevention;Fundamentals of Cancer Prevention;2013-09-12